Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma

NCT01927419 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

142

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable Melanoma
Metastatic Melanoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: Placebo

Sponsor

Bristol-Myers Squibb